Researchers say ‘auto-antibodies’ could play a major role in how cancer develops
I would like to be emailed about offers, events and updates from The Independent. Read our Privacy notice
A class of proteins in the immune system could play a role in keeping some people safe from cancer despite lifelong exposure to risks, scientists say.
Humans have billions of different proteins in the body known as antibodies that are randomly produced by the immune system to bind to molecules found on bacteria, viruses, fungi, toxins or allergens.
Antibodies help the body fight off infections, either by marking pathogens for destruction by immune cells or directly neutralising them.
However, in some people, antibodies may mistakenly bind to normal molecules in their own body and cause their immune system to attack healthy cells and tissues.
Previous research has shown that these “autoantibodies”, or auto-Abs, can target molecules that the immune system uses to fight infectious diseases.
Such auto-Abs have also been linked to infectious diseases and inflammatory conditions.
Now, scientists suspect developing ways to control auto-Abs in cancer can help patients reduce their disease severity.
"There is ample evidence that the immune system plays a significant role in cancer," said Laurent Casanova, a professor in the Children's Medical Centre Research Institute at UT Southwestern (CRI).
"Our job will be to determine if there are auto-Abs that could offer protection against cancer or drive cancer outcomes,” Dr Casanova said.
Scientists have so far discovered auto-Abs that bind to about a dozen of the 50 or so known immune system molecules called cytokines.
The discoveries have led to treatment methods called immunotherapies, including the now popular checkpoint inhibitor drugs and chimeric antigen receptor (CAR)-T cells.
These therapies have bolstered the theory that auto-Abs indeed influence cancer development and growth, explaining why some people remain cancer-free despite lifelong risks.
“Antibody repertoires, including autoantibodies targeting immune pathways, may shape cancer immunosurveillance,” scientists wrote.